M
Matthew J. Fuchter
Researcher at Imperial College London
Publications - 159
Citations - 6834
Matthew J. Fuchter is an academic researcher from Imperial College London. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 36, co-authored 134 publications receiving 4871 citations. Previous affiliations of Matthew J. Fuchter include Emory University & University of London.
Papers
More filters
Journal ArticleDOI
Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets
Matthias G. J. Baud,Thomas Leiser,Patricia Haus,S.S. Samlal,Ai Ching Wong,Robert J.K. Wood,Vanessa Petrucci,Mekala Gunaratnam,Siobhan M. Hughes,Lakjaya Buluwela,Fabrice Turlais,Stephen Neidle,Franz-Josef Meyer-Almes,Andrew J. P. White,Matthew J. Fuchter +14 more
TL;DR: By direct in vitro assay of the free thiol generated upon reduction of the dimeric psammaplin scaffold, it is unambiguously demonstrated that 11c functions as a natural prodrug, with the reduced form being highly potent against HDAC1 in vitro (IC(50) 0.9 nM).
Journal ArticleDOI
500-Fold Amplification of Small Molecule Circularly Polarised Luminescence through Circularly Polarised FRET
Jessica Wade,Jochen R. Brandt,David Reger,Francesco Zinna,Konstantin Amsharov,Norbert Jux,David L. Andrews,Matthew J. Fuchter +7 more
TL;DR: It is proposed that the amplification arises not simply through a chiral environment effect, but instead due to electrodynamic coupling between the electric and magnetic transition dipoles of the polymer donor and superhelicene acceptor, and subsequent CP Förster resonance energy transfer.
Journal ArticleDOI
A high throughput screen for next-generation leads targeting malaria parasite transmission
Michael J. Delves,Celia Miguel-Blanco,Celia Miguel-Blanco,Holly Matthews,Irene Molina,Andrea Ruecker,Sabrina Yahiya,Ursula Straschil,Matthew Abraham,María Luisa León,Oliver J. Fischer,Ainoa Rueda-Zubiaurre,Jochen R. Brandt,Alvaro Cortes,Anna Barnard,Matthew J. Fuchter,Félix Calderón,Elizabeth A. Winzeler,Robert E. Sinden,Esperanza Herreros,Francisco J. Gamo,Jake Baum +21 more
TL;DR: A high-throughput screen of potential antimalarial compounds, identifying seventeen drug-like molecules specifically targeting transmission, providing a previously unexplored base from which future therapeutics can be developed, capable of preventing parasite transmission through the population.
Journal ArticleDOI
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel,Manikandan Periyasamy,Georgina P. Sava,Alexander Bondke,B. W. Slafer,Sebastian H. B. Kroll,Marion Barbazanges,Richard Starkey,Silvia Ottaviani,Alison Harrod,Eric O. Aboagye,Laki Buluwela,Matthew J. Fuchter,Anthony G. M. Barrett,R. Charles Coombes,Simak Ali +15 more
TL;DR: The findings reveal that CDK7 inhibition provides a new approach, especially for ER-positive breast cancer and identify ICEC0942 as a prototype drug with potential utility as a single agent or in combination with hormone therapies for breast cancer.
Journal ArticleDOI
A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration.
Dean A. Heathcote,Hetal Patel,Sebastian H. B. Kroll,Pascale Hazel,Manikandan Periyasamy,Mary Alikian,Seshu K. Kanneganti,Ashutosh S. Jogalekar,Bodo Scheiper,Marion Barbazanges,Andreas Blum,Jan Brackow,Alekasandra Siwicka,Robert D M Pace,Matthew J. Fuchter,James P. Snyder,Dennis C. Liotta,Paul S. Freemont,Eric O. Aboagye,R. Charles Coombes,Anthony G. M. Barrett,Simak Ali +21 more
TL;DR: 4k is identified as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients and Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.